智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司子公司上海恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-3836注射液的《药物临床试验批准通知书》,将于近期开展临床试验。
SHR-3836注射液是公司自主研发的创新型抗肿瘤药物,拟用于治疗多发性骨髓瘤。经查询,目前国内外尚无同类药上市。截至目前,SHR-3836注射液相关项目累计研发投入约3,170万元(未经审计)。
智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司子公司上海恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-3836注射液的《药物临床试验批准通知书》,将于近期开展临床试验。
SHR-3836注射液是公司自主研发的创新型抗肿瘤药物,拟用于治疗多发性骨髓瘤。经查询,目前国内外尚无同类药上市。截至目前,SHR-3836注射液相关项目累计研发投入约3,170万元(未经审计)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.